Inside Precision Medicine April 22, 2024
“Next generation” weight loss drug developer Metsera just launched with $290M in funding. Backed by Population Health Partners and ARCH Venture Partners and led by former executives of The Medicines Company, Metsera has a broad portfolio of oral and injectable incretin, non-incretin, and combination therapies designed to address multiple targets.
“Metsera was purpose-built over the last two years to get ahead of the innovation curve in one of the largest and fastest growing markets in the history of biopharma,” said Clive Meanwell, the new company’s chief executive officer.
Since the launch of GLP-1 agonists (e.g. Ozempic and Wegovy), the weight loss market has been booming, with high prices and long use leading to big profits. GLP-1s are a class...
Today's Sponsors
Today's Sponsor